Novo Nordisk Builds Out Metabolic Pipeline With $2.6 Billion China Deal as Real-World Data Backs Semaglutide

Novo Nordisk pays $300M upfront for Hengrui's weekly oral obesity candidate and touts semaglutide's cardiovascular edge over tirzepatide.

Novo Nordisk has moved to shore up its metabolic franchise on two fronts, licensing a weekly oral obesity candidate from China's Jiangsu Hengrui Pharma while releasing real-world evidence that its existing blockbuster semaglutide holds an edge over rival tirzepatide on cardiovascular outcomes.

The Danish drugmaker is paying $300 million upfront for exclusive development and commercialization rights to HRS-1596 outside Greater China, with a further $2.3 billion tied to hitting development, regulatory and sales milestones — a total package of up to $2.6 billion. Hengrui keeps the rights in mainland China, Hong Kong, Macau and Taiwan, and will also collect royalties on net sales in the licensed territories. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory clearances.

HRS-1596 is an experimental GLP-1/GIP dual agonist that Chinese regulators have already cleared for phase 1 trials in weight management and type 2 diabetes. The appeal lies in its once-weekly oral dosing, which would remove the need for injections — though whether that profile holds up in practice will depend on the upcoming clinical readout on efficacy and tolerability.

Cardiovascular Edge in Focus

The licensing news landed alongside retrospective data covering 636,525 adults with type 2 diabetes, which showed that escalating the semaglutide dose cut the risk of major cardiovascular events by 6 percent compared with switching patients to Eli Lilly's tirzepatide. Novo Nordisk disclosed the findings yesterday, positioning them as a rebuttal to its main competitor at a moment when payers and physicians are paying closer attention to outcomes beyond raw weight loss, such as vascular damage and heart attacks.

The company has been stacking up clinical wins. On September 21 it published initial results from the phase 3 REIMAGINE 5 trial, in which the combination therapy CagriSema at a 1.0 mg / 1.0 mg dose delivered an estimated average weight reduction of 12.4 percent, against 9.1 percent for participants on 5 mg of tirzepatide. CagriSema is slated for launch in early 2027.

Novo Nordisk also presented observational data from 194 patients who switched from injections to the oral Wegovy pill: over three months, they shed an average of 4 percent more body weight.

Broadening the Technology Base

Beyond the Hengrui pact, the company has been shopping externally to widen its technological reach. On Friday it secured rights to Swedish firm Nanexa's PharmaShell platform technology for up to five development programs spanning obesity, type 2 diabetes and cardiometabolic disease.

The flurry of dealmaking reflects a pressing strategic need. Novo Nordisk faces the looming loss of patent protection on semaglutide in Europe and the US in the early 2030s, and competition from Eli Lilly and a crowded field of obesity candidates in development is intensifying.

Analysts are taking a measured view of the Hengrui transaction. BMO's Evan Seigerman sees long-term differentiation potential in the oral dual agonist but expects no material near-term impact on operations. Portfolio manager Markus Manns of Union Investment welcomed the agreement while noting that Novo Nordisk needs larger acquisitions involving more advanced assets.

Shares Stay Under Pressure

The market gave the licensing announcement little credit. Novo Nordisk traded at EUR 33.41, down 1.1 percent on the day, after closing the prior session at EUR 33.77 for a 0.9 percent loss. The stock has surrendered 24 percent since the start of the year, leaving it well below its highs; a separate tally put the year-to-date decline at 23 percent.

Institutional sentiment remains cautious. Deutsche Bank trimmed its price target on September 22 to 245 DKK from 265 DKK, keeping a sell rating, while Bank of America Securities assigned the shares a "Hold" rating on Friday. For investors, the question is whether the clinical data advantages Novo Nordisk is amassing will be enough to ease the pressure building in the cardiometabolic market.